Literature DB >> 24088159

Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.

Susannah L Rose1.   

Abstract

Patient advocacy organizations (PAOs) advocate for increased research funding and policy changes and provide services to patients and their families. Given their credibility and political clout, PAOs are often successful in changing policies, increasing research funding, and increasing public awareness of medical conditions and the problems of their constituents. In order to advance their missions, PAOs accept funding, frequently from pharmaceutical firms. Industry funding can help PAOs advance their goals but can also create conflicts of interest (COI). Research indicates that bias may occur, even among well-meaning professionals, when people and organizations have financial COI. Industry funding may therefore influence PAOs to act in ways that favor the interests of their donors, which may increase the risk of harm to patients. This article extends the analysis developed in the Institute of Medicine report, Conflicts of Interest in Medical Research, Education, and Practice, and applies the analysis to understand PAOs and their relationships with industry. It argues that the preferred goal of institutional COI policies should not be to promote trust, but to promote trustworthiness and appropriately placed trust.
© 2013 American Society of Law, Medicine & Ethics, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24088159      PMCID: PMC4107906          DOI: 10.1111/jlme.12078

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  43 in total

1.  Industry funding of patients' support groups: declaration of competing interests is rare in Italian breast cancer associations.

Authors:  Paola Mosconi
Journal:  BMJ       Date:  2003-08-09

2.  Drug companies told that sponsoring patients' groups might help win approval for their products.

Authors:  Bob Burton
Journal:  BMJ       Date:  2005-12-10

3.  Whose deaths matter? Mortality, advocacy, and attention to disease in the mass media.

Authors:  Elizabeth M Armstrong; Daniel P Carpenter; Marie Hojnacki
Journal:  J Health Polit Policy Law       Date:  2006-08       Impact factor: 2.265

4.  Sunshine laws and the pharmaceutical industry.

Authors:  Troyen A Brennan; Michelle M Mello
Journal:  JAMA       Date:  2007-03-21       Impact factor: 56.272

5.  Should patient groups accept money from drug companies? No.

Authors:  Barbara Mintzes
Journal:  BMJ       Date:  2007-05-05

6.  Should patient groups accept money from drug companies? Yes.

Authors:  Alastair Kent
Journal:  BMJ       Date:  2007-05-05

7.  Everyone's a little bit biased (even physicians).

Authors:  Daylian M Cain; Allan S Detsky
Journal:  JAMA       Date:  2008-06-25       Impact factor: 56.272

8.  The increasingly complex world of cancer patient advocacy organizations.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

9.  Understanding financial conflicts of interest.

Authors:  D F Thompson
Journal:  N Engl J Med       Date:  1993-08-19       Impact factor: 91.245

10.  Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.

Authors:  Douglas E Ball; Klara Tisocki; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2006-08-03       Impact factor: 3.295

View more
  18 in total

1.  Beyond Consent: Building Trusting Relationships With Diverse Populations in Precision Medicine Research.

Authors:  Stephanie A Kraft; Mildred K Cho; Katherine Gillespie; Meghan Halley; Nina Varsava; Kelly E Ormond; Harold S Luft; Benjamin S Wilfond; Sandra Soo-Jin Lee
Journal:  Am J Bioeth       Date:  2018-04       Impact factor: 11.229

2.  Examining Physician Interactions with Disease Advocacy Organizations.

Authors:  Caroline Horrow; Joel E Pacyna; Carol Cosenza; Richard R Sharp
Journal:  AJOB Empir Bioeth       Date:  2019-08-26

Review 3.  The role of brain tumor advocacy groups.

Authors:  Michele Rhee; Paulius Mui; Carl Cadogan; Jonny Imerman; Sarah Lindsell; Lainey Titus Samant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

4.  Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.

Authors:  David G Li; Sean Singer; Arash Mostaghimi
Journal:  JAMA Dermatol       Date:  2019-04-01       Impact factor: 10.282

5.  Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.

Authors:  Emily A Largent; Andrew Peterson; Jason Karlawish; Holly Fernandez Lynch
Journal:  Drugs Aging       Date:  2022-06-13       Impact factor: 4.271

Review 6.  The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review.

Authors:  Christina Q Nguyen; Kristine Alba-Concepcion; Elizabeth E Palmer; Jackie L Scully; Nicole Millis; Michelle A Farrar
Journal:  Orphanet J Rare Dis       Date:  2022-04-18       Impact factor: 4.303

7.  Association of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study.

Authors:  James S Yeh; Kirsten E Austad; Jessica M Franklin; Susan Chimonas; Eric G Campbell; Jerry Avorn; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2014-10-14       Impact factor: 11.069

Review 8.  Corporate practices and health: a framework and mechanisms.

Authors:  Joana Madureira Lima; Sandro Galea
Journal:  Global Health       Date:  2018-02-15       Impact factor: 4.185

Review 9.  Psychiatrization of Society: A Conceptual Framework and Call for Transdisciplinary Research.

Authors:  Timo Beeker; China Mills; Dinesh Bhugra; Sanne Te Meerman; Samuel Thoma; Martin Heinze; Sebastian von Peter
Journal:  Front Psychiatry       Date:  2021-06-04       Impact factor: 4.157

10.  Same song, different audience: pharmaceutical promotion targeting non-physician health care providers.

Authors:  James S Yeh; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2013-11-26       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.